Cambiotics

Cambiotics is a biotechnology and health supplement company focused on developing precision-formulated probiotic products designed to support the body's natural removal of per- and polyfluoroalkyl substances (PFAS), commonly known as 'forever chemicals.' The company occupies a highly specialized niche at the intersection of microbiome science and environmental health, targeting one of the most pressing public health concerns of the modern era.

The company's core product is a proprietary probiotic formulation containing specialized bacterial strains that have been shown in scientific studies to bioaccumulate PFAS from their surrounding environment. These strains are specifically selected for their ability to interact with PFAS molecules within the gut and support their clearance through the digestive system. The scientific foundation for this approach is grounded in research indicating that certain gut bacteria interact with PFAS compounds, potentially offering a novel biological pathway to reduce their accumulation in the human body.

Cambiotics targets consumers and populations with elevated PFAS exposure, including workers in chemical manufacturing, firefighting, textile production, and related industries, as well as the general population exposed through contaminated drinking water and food sources. With over 99% of the global population estimated to have detectable PFAS levels in the body, the addressable market is exceptionally broad. The company also partners with Quest Diagnostics — available at over 2,300 centers across the United States — to offer PFAS blood testing, enabling consumers to monitor their individual PFAS burden before and during product use.

As of the time of publication, Cambiotics' probiotic product is in a pre-launch phase, with availability in the United States anticipated in 2026. International inquiries from Europe, Asia, and Africa are being handled through direct sales channels. The company is currently building a waitlist for early access in the U.S. market.

The company's scientific credibility is bolstered by association with academic research, including work from Professor Kiran Raosaheb Patil of the University of Cambridge, whose findings on gut bacteria and PFAS interaction inform the product's mechanism of action. Cambiotics positions itself at the forefront of a nascent but rapidly growing segment of the nutraceutical and functional health market, where environmental toxin mitigation through microbiome intervention represents a compelling and differentiated value proposition.